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Transcatheter aortic valve implantation (TAVI) has great
promise of helping patients with severe aortic valve disease
who are not candidates for open surgery. It is an expensive
technology, however, and some believe it should not be of-
fered to every patient who is medically suitable to receive
it—in other words, its use should be rationed.
The Ethics Forum, which comprises the membership of
the American Association for Thoracic Surgery Ethics
Committee and the Society of Thoracic Surgeons Standards
and Ethics Committee, sponsored a debate on rationing
TAVI at the 2011 Annual Meeting of the American Associ-
ation for Thoracic Surgery. John E. Mayer, Jr, MD, argued
the proponent position,1 Grayson H. Wheatley, MD, the
contrariant2 regarding a hypothetical case, constructed to
focus on the question of whether the offer of TAVI should
be withheld from an elderly patient.
THE CASE OF THE OLD MAN AND HIS VALVE
The patient is 75 years old, and 10 years ago he received
a 4-vessel coronary artery bypass graft, including the left in-
ternal thoracic artery to the left anterior descending coro-
nary artery. He did well thereafter but has lived alone
since his wife died 2 years ago; he has no children and no
close relatives. Significant heart failure symptoms recently
developed in the patient. Echocardiographic assessment
now shows evidence of severe aortic stenosis with a calcu-
lated valve area of 0.8 cm2 and a mean gradient across the
valve of 60 mm Hg. There is left ventricular hypertrophy,
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The Journal of Thoracic and Cacatheterization shows severe native coronary disease with
all grafts patent and no new native coronary obstructions.
Computed tomography scan reveals evidence of moderate
to severe calcification of the ascending aorta, and the left in-
ternal thoracic artery passes directly under the sternum, and
thus is at high risk of being damaged during reoperative
sternotomy. In addition, the patient has moderate to severe
chronic obstructive pulmonary disease (forced expiratory
volume in 1 second 45% of normal) and a baseline creati-
nine of 1.8 mg/d.
The patient is referred to Dr Sloan, an established cardio-
thoracic surgeon who participated in the initial Sapien (Ed-
wards Lifesciences, Irvine, Calif) TAVI trial and has
significant expertise with the procedure. Although Dr Sloan
has determined that the patient is a medically acceptable
candidate for TAVI, but not for aortic valve replacement,
he wonders whether some advanced technologies such as
this one are expanding the scope of health care beyond sus-
tainable limits. He knows that the only reason to deny TAVI
to this particular patient is consideration of nonmedical is-
sues, that is, the patient’s advanced age and lack of a social
support system, and the expense of the procedure, and is un-
decided whether he should offer the procedure or, for the
greater good, deny him its benefits.COMMENT ON THE DEBATE
In the accompanying point–counterpoint discussion, Drs
Mayer1 and Wheatley2 wrestle with this question. Both
writers consider neither age nor social status to be a critical
determinant in deciding whether or not the procedure
should be offered. Wheatley considers the question on the
basis of financial analysis and 3 ethical principles: need,
maximizing, and egalitarian. He concludes that the patient
should be offered TAVI under the first 2 but perhaps not
the last (the egalitarian principle of justice). Looking to
the future, he is concerned about increasing pressures on
physicians to carry out just such rationing.
Mayer1 takes a broader approach, looking at the issue
from a systemic viewpoint. He distinguishes between the
role of physicians as caregivers and as members of the med-
ical profession, stating that the profession as a whole has
a responsibility to control and monitor (which he considers
to be different from rationing) the use of expensive technol-
ogies. Although he speaks of ‘‘controlled dissemination of
this technology,’’ Mayer also believes the information gen-
erated by this process will be sufficient for physicians and
patients to make decisions that respect the interests of
both patients and society. He does not directly answer the
question of whether the physician in the vignette wouldrdiovascular Surgery c Volume 143, Number 4 769
Point/Counterpoint Sadebe justified in not offering TAVI to a medically eligible pa-
tient because of high cost to society.
Bedside rationing is a relatively new role for physicians,
yet the foundation of the healing relationship is the pa-
tient’s trust that physicians will be primarily concerned
for the patient’s interests rather than their own or society’s
interests. Nearly every current code of ethics, including
those of the American Association for Thoracic Surgery,3
the Society of Thoracic Surgeons,4 and the American Med-
ical Association,5 places the interests of the patient as
physicians’ paramount responsibility. Bedside ration-
ing—withholding the offer of a particular therapy from
one’s own patient despite a positive benefit–harm bal-
ance—is prima facie inconsistent with this responsibility.
Both discussants recognize the primary obligation of
physicians to patients. Wheatley2 believes bedside ration-
ing of expensive new technologies will likely have to be
rationed in the future.
Mayer,1 however, believes rationing can be avoided if
rigorous data provided by the profession’s monitoring of
TAVI are used by physicians and patients for rational con-
sideration, enabling the physician and patient together to
limit TAVI to those who will benefit most. In the case pre-
sented, TAVI was medically indicated, but Dr Sloan won-
dered about how to weigh age, social situation, and cost
in deciding whether to offer the procedure to the patient.
Both discussants agree that age and social status are not de-
terminants of suitability for TAVI, so cost remains as the
central nonmedical issue. Mayer couples ‘‘control’’ of
TAVI with monitoring, but it is unclear what it means to
control a technology when ‘‘it will be critical that the pa-
tients be provided this information so that each may make770 The Journal of Thoracic and Cardiovascular Surgtheir own decisions.’’ In the presence of a positive bene-
fit–harm balance, it is difficult to imagine patients refusing
an offer of a life-prolonging, quality of life–improving pro-
cedure on the basis of avoiding an expense that will not be
borne by either them or their survivors.
Critical to this discussion is current law and future policy
development. The legislative battles over revisions of the
Patient Protection and Affordable Care Act that are cur-
rently under way in Washington will eventually produce
a health care system that will ultimately determine the
shape and nature of the patient–physician relationship.
Some reforms will empower physicians and patients to
make clinical decisions, and others will relegate much deci-
sion making to external agencies. Resolution of the ration-
ing debate awaits the precise configuration of our
developing health care system, as determined by the ongo-
ing deliberations in Congress and the pending decision of
the US Supreme Court on the constitutionality of the Af-
fordable Care act.6References
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